Ranitidine in the treatment of duodenal and prepyloric ulcer: comparison of two dosage regimens.
In a double-blind controlled study eight-two patients with duodenal or prepyloric ulcer were treated with either 100 mg of 150 mg ranitidine twice daily. After 4 weeks of treatment the ulcer had healed in twenty-two of forty-one patients (54%) on 200 mg of ranitidine and in thirty-six of forty-one patients (88%) on 300 mg of ranitidine. In the x2-test this difference was statistically significant (p less than 0.01). Relief of pain and reduction of mucosal inflammation were similar in both groups. There were no drug-related side-effects nor consistent changes in laboratory findings. We conclude that a daily dose of 300 mg ranitidine is superior to 200 mg ranitidine in the treatment of duodenal and prepyloric ulcer and that the short-term use of ranitidine seems to be safe for the treatment of these ulcers.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005663:Furans / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D011899:Ranitidine; D013276:Stomach Ulcer / Q000188:drug therapy*
D005663:Furans; D011899:Ranitidine